Information Provided By: 
Fly News Breaks for February 22, 2017
TGTX
Feb 22, 2017 | 07:33 EDT
Aegis analyst Jason Wittes initiated TG Therapeutics with a Buy and a $26 price target saying the company looks to package its two lead oncology drugs in Phase 3 trials, TG-101 and TGR-1202, as combination therapies at very competitive prices versus combination therapies from two different sources, which is particularly important to payers treating lymphomas and other less aggressive cancers with prolonged treatment regimes. Wittes expects TG to make rapid progress through the clinic and emphasize the importance of owning multiple assets.
News For TGTX From the Last 2 Days
TGTX
Apr 19, 2024 | 10:46 EDT
Bullish option flow detected in TG Therapeutics with 1,058 calls trading, 1.2x expected, and implied vol increasing over 2 points to 100.79%. Jun-24 12 puts and Jun-24 17 calls are the most active options, with total volume in those strikes near 600 contracts. The Put/Call Ratio is 0.46. Earnings are expected on April 29th.
TGTX
Apr 18, 2024 | 12:48 EDT
TGTX
Apr 18, 2024 | 07:33 EDT
